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Purpose: Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder of connective tissue, affecting the retina,
the skin, and the cardiovascular system. PXE is caused by mutations in ABCC6. Up to now, the literature reports that there
are 180 different ABCC6 mutations in PXE. The purpose of this paper is to report eight novel mutations in ABCC6 and
to update the spectrum and frequency of ABCC6 mutations in PXE patients.
Methods: Eye, skin, and DNA examinations were performed using standard methodologies. We newly investigated the
gene in 90 probands by denaturing high-performance liquid chromatography (dHPLC) and direct sequencing. We
examined a total of 166 probands.
Results: Eight novel ABCC6 mutations (c.1685T>C, p.Met562Thr; c.2477T>C, p.Leu826Pro; c.2891G>C, p.Arg964Pro;
c.3207C>A,  p.Tyr1069X;  c.3364delT,  p.Ser1122fs;  c.3717T>G,  p.Tyr1293X;  c.3871G>A,  p.Ala1291Thr;  c.
4306_4312del, p.Thr1436fs) were found in seven unrelated patients. Currently, our mutation detection score is at least
one ABCC6 mutation in 87% of patients with a clinical diagnosis of PXE.
Conclusions: Our results support that ABCC6 is the most important, and probably the only, causative gene of PXE. In
total, 188 different ABCC6 mutations have now been reported in PXE in the literature.
Pseudoxanthoma elasticum (PXE; OMIM 264800) is a
heritable disorder of connective tissue, affecting the skin,
retina,  and  blood  vessels.  The  most  frequent  retinal
abnormalities  are  peau  d’orange,  angioid  streaks,  and
punched-out white chorioretinal lesions, which are visible as
white dots sometimes with a comet-like tail. Angioid streaks
develop in almost all of the patients and often lead to choroidal
neovascularization, subretinal hemorrhages, and visual loss.
Skin abnormalities usually start at the lateral sides of the neck
with yellowish papules that confluence into plaques. Skin of
other flexural sides of the body often follows the same course,
and sometimes the skin abnormalities progress to redundant
folds.  Patients  have  an  increased  risk  of  cardiovascular
complications  including  gastro-intestinal  bleedings  and
arteriosclerosis. The expression of the disease is variable, and
substantial clinical differences exist between patients, even
within families [1,2].
PXE is caused by mutations in a single gene, ABCC6
[3-5]. The inheritance is autosomal recessive. Recent clinical
Correspondence  to:  Professor  Arthur  A.B.  Bergen,  Ph.D.,
Department  of  Clinical  and  Molecular  Ophthalmogenetics,
Netherlands Institute for Neuroscience, an Institute of the Royal
Netherlands Academy of Arts and Sciences KNAW, Meibergdreef
47, 1105 BA Amsterdam, The Netherlands; Phone: (31) 20 5666101;
FAX: (31) 20 5666121; email: a.bergen@nin.knaw.nl
and  molecular  studies  showed  that  putative  dominant
segregating PXE pedigrees are probably the result of mild
expressions in heterozygous carriers or pseudodominance due
to an unexpected high carrier frequency in the population
[6-9].
ABCC6 belongs to the ATP-binding cassette (ABC) gene
sub-family C [10,11]. ABCC6 has 31 exons spanning about
73 kb genomic DNA. The mRNA is approximately 6 kb with
an open reading frame (ORF) of 4.5 kb. The ABCC6 protein
consists of 1,503 amino acids and contains 17 transmembrane-
spanning domains and two intracellular nucleotide binding
folds (NBFs). The NBFs consist of Walker A and B domains
and a C motif critical for active ATP dependent transport
across the cell membrane [1,12]. The putative ABCC6 protein
structure is presented in Figure 1. Two ABCC6 pseudogenes,
homologous to, respectively, the first four and nine exons of
ABCC6,  have  been  identified  [13,14],  complicating  the
mutational analysis of the gene [15].
ABCC6  is  highly  expressed  in  the  liver  and  kidney.
Expression in multiple other tissues including those affected
by PXE (skin, retina, and vessel walls) is low or absent. The
protein was localized to the basolateral membranes of both
hepatocytes in the liver and the proximal kidney tubules. The
natural substrate transported by the ABCC6 protein remains
to  be  identified.  Functional  studies  showed  that  ABCC6
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118transports glutathione S-conjugate leukotriene C(4), S-(2,4-
dinitrophenyl) glutathione, and the cyclopentapeptide BQ123
[16-18]. The present view is that ABCC6 transports substrates
from the liver and kidney cells back into the blood [10,18].
Up to now, 180 different mutations in ABCC6 have been
reported (Appendix 1). Mutations were found throughout the
gene, but there is a high concentration in and around the NBFs
and in the eighth cytoplasmatic loop [7,9,12,19-21]. Mutation
detection rates varied from 55%-97% among the different
studies.
The  purpose  of  this  paper  was  to  report  eight  novel
mutations in ABCC6 and to update the mutation spectrum and
frequency of ABCC6 mutations in PXE patients.
METHODS
DNA of all probands/families (n=166) was collected by one
of us or sent to the Netherlands Institute for Neuroscience, a
referral center for geneticists and ophthalmologists from the
Netherlands  and  other  European  countries,  for  mutational
analysis of ABCC6. The patients, who had novel mutations,
were clinically examined by one of us (A.P., B.C., H.K., A.M.,
P.dJ.) except for cases 4 and 7, and data from dermatologic,
ophthalmic, and cardiovascular examinations elsewhere were
collected.  The  dermatologic  examination  consisted  of  an
inspection of the skin and histopathology of a skin biopsy. The
ophthalmic  examination  included  an  assessment  of  visual
acuity,  slit-lamp  examination  of  the  anterior  segment,
biomicroscopy with a 90 diopter lens of the posterior pole of
the eye fundus, indirect ophthalmoscopy of the peripheral
retina, and digital photography of as many of the fundus signs
as feasible. The cardiovascular examination included at least
measurement  of  blood  pressure,  electrocardiography,  and
echocardiography.  The  clinical  diagnosis  of  PXE  was
considered  definite  if  at  least  two  of  the  three  following
criteria were met: characteristic skin lesions at the lateral side
Figure 1. Schematic representation of the MRP6 protein. The protein
contains  17  membrane-spanning  domains  and  two  intracellular
nucleotide binding folds (NBFs). The percentages in the figure show
how the mutations in our population are distributed over the different
domains of the protein. The eighth cytoplasmatic loop is the most
frequently mutated domain, followed by the region between the last
transmembrane-spanning domain and NBF2 and by NBF2 itself.
Del=deletion. In addition, 1% of the population had a deletion of the
whole gene.
of  the  neck  and/or  other  flexural  regions  of  the  body,
fragmentation  and  calcification  of  elastic  fibers  in  a  skin
biopsy,  and  characteristic  retinal  lesions  (peau  d’orange,
angioid  streaks,  and/or  punched-out  white  chorioretinal
lesions).
DNA was isolated from peripheral blood by standard
techniques.  Polymerase  chain  reaction  (PCR)  primers,
amplification conditions, and mutation analysis strategy were
essentially performed as described previously [22]. After pre-
screening  for  common  mutations,  all  coding  exons  were
screened  by  denaturing  high-performance  liquid
chromatography (dHPLC). Exonic fragments with changed
dHPLC patterns were further analyzed by direct sequencing.
The  known  deletions  of  exons  23–29  and  exon  15  were
analyzed as described [22].
The nomenclature for mutations was based on previously
published recommendations [23] and additional guidelines.
The  ABCC6  cDNA  consensus  sequence  (GenBank
AF076622) was used for DNA mutation description.
When a novel mutation was found, at least 140 control
chromosomes were screened for this mutation. The controls
were Caucasian individuals without any eye disease or any
other apparent disorder. When the mutation was a missense
mutation,  conservation  of  the  changed  amino  acid  was
checked  by  ClustalW  multiple  sequence  alignment
comparison for ABCC6 or other closely related proteins in
Felis  catus,  Gallus  gallus,  Monodelphis  domestica,  Mus
musculus, Ornythorhynchus anatinus, Otolemur garnetii, Pan
troglodytes,  and  Rattus  norvegicus.  An  amino  acid  was
considered to be conserved when it was present in multiple
proteins in these animals.
RESULTS
We  found  eight  novel  ABCC6  mutations  (c.1685T>C,  c.
2477T>C, c.2891G>C, c.3207C>A, c.3364delT, c.3717T>G,
c.3871G>A, and c.4306_4312del). None of these mutations
were present in the control chromosomes. The eight novel
mutations were found in seven patients in whom the clinical
diagnosis of PXE was unambiguously established. All had
characteristic skin abnormalities (Figure 2) either confirmed
by  a  skin  biopsy  or  in  combination  with  characteristic
ophthalmologic signs or by both (Table 1). Below, we present
the molecular data in detail together with family data where
relevant.
In case 1, analysis of ABCC6 revealed two mutations, the
earlier  reported  c.3662G>A  (p.Arg1221His)  [24]  and  the
novel mutation c.1685T>C (Met562Thr). This latter missense
mutation changes a well conserved amino acid at the fifth
extracellular loop of the protein.
In case 2, we found the previously reported pathogenic
sequence change, c.2787+1G>T, in intron 21 of ABCC6 [25,
26] and the novel mutation, c.2477T>C (p.Leu826Pro), in
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119exon 19. This missense mutation is located just after NBF1
and leads to the change of a well conserved amino acid.
In case 3, one missense mutation was found in ABCC6,
the novel mutation c.2891G>C (p.Arg964Pro), which leads to
the change of a well conserved amino acid between NBF1 and
NBF2. No second mutation was found.
In case 4, we found a c.3207 C>A (p.Tyr1069X) nonsense
mutation as well as a c.3871G>A (p.Ala1291Thr) missense
mutation in ABCC6. Both mutations have not been reported
before.  The  former  mutation  theoretically  results  in  a
premature chain termination and an absent or dysfunctional
protein. The latter mutation changes a well conserved amino
acid in NBF2.
Figure 2. Clinical skin features of pseudoxanthoma elasticum. Mild
but characteristic skin features, consisting of papules (as indicated
by an arrow) and redundant skin folds as shown on the right side of
the neck of case 1. In a later stage the papules can confluence into
plaques.
In case 5, two mutations were found in ABCC6, the well-
known deletion of exon 23–29 and the novel mutation, c.
3364delT. The angioid streaks and peau d’orange of the retina
of her right eye can be observed in Figure 3. She had minimal
skin abnormalities at the lateral side of her neck, just below
the hair line, which were not noticed before. Her father also
had a clinical diagnosis of PXE. He had peau d’orange of the
retina,  angioid  streaks,  and  macular  degeneration  after
subretinal neovascularization in both eyes. The dermatologist
did not find characteristic skin lesions, but a skin biopsy from
the left side of the neck showed clumping and calcification of
elastic fibers. He had the exon 23–29 deletion. The mother of
case 5 had the c.3364delT mutation. We did not find a second
mutation in the father.
Case  6  was  homozygous  for  a  novel  mutation  in
ABCC6, c.3717T>G leading to a stop codon at position 1239
of the protein (p.Tyr1239X) just before NBF2. The patient’s
sister was said to be affected as well. Consanguinity between
the parents was denied.
Mutational analysis of ABCC6 in case 7 revealed the
earlier reported mutation, c.4015C>T (p.Arg1339Cys) [25],
and the novel mutation, c.4306_4312del. This new mutation
theoretically leads to a frameshift and the introduction of a
stop codon at position 1461 of the protein.
In our entire data set, we found two causative ABCC6
mutations in 76 of 166 (46%) PXE probands and only a single
mutation in 51 (31%) probands. In 39 (23%) probands, we did
not find any mutation. PXE had been diagnosed in 19 of these
patients. In the remaining 20 patients, there was either doubt
about the diagnosis or not enough clinical data to prove the
diagnosis. Thus at least one mutation was found in 127 (87%)
of  146  probands  in  whom  the  clinical  diagnosis  was
established a priori. This means that we found mutations in
203 (69.5%) out of 292 alleles. The type and frequencies of
the different mutations found are listed in Appendix 1. Part of
TABLE 1. SUMMARY OF THE DEMOGRAPHIC AND CLINICAL DATA OF THE PATIENTS WITH NOVEL MUTATIONS




Skin Biopsy Eyes CV Fam
1 c.3662G>A c.1685T>C F 28 E 16 +
(Figure 2)
+ as n neg
2 c.2787+1G>T c.2477T>C M 13 GB 10 + + n n neg
3 c.2891G>C - F 31 GB 29 + nd as n ?
4 c.3207C>A c.3871G>A M 36 NL ? + + ? ? ?
5 del exon 23–29 c.3364delT F 29 NL 29 + + pdo, as
(Figure 3)
? pos
6 c.3717T>G c.3717T>G F 25 TR 19 + + pdo, as, co mi pos
7 c.4015C>T c.4306_4312del F 43 S ? + ? as n neg
The diagnosis of pseudoxanthoma elasticum (PXE) can be made if a case has at least two of the following criteria: characteristic
skin lesions, characteristic abnormalities in a skin biopsy, characteristic retinal lesions. Based on these criteria, all of our cases
have a definite diagnosis of PXE. No genotype-phenotype correlations can be made in this small group. +=affected, as=angioid
streaks,  co=comet-like  lesions,  cv=cardiovascular,  E=Spain,  F=female,  fam=family  history,  GB=Great  Britain,  M=male,
mi=mitral valve insufficiency, n=normal, nd=not done, neg=negative, NL=Netherlands, pdo=peau d’orange, pos=positive,
S=Sweden, TR=Turkey, yrs=years, ?=no information, novel mutations are bold and underlined.
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120the patient and mutation data described here was published
previously [19,22].
DISCUSSION
In this study, eight novel mutations were found, which we
consider to be implicated in PXE: c.1685T>C (p.Met562Thr),
c.2477T>C  (p.Leu826Pro),  c.2891G>C  (p.Arg964Pro),  c.
3207C>A  (p.Tyr1069X),  c.3364delT  (p.Ser1122fs),  c.
3717T>G (p.Tyr1293X), c.3871G>A (p.Ala1291Thr), and c.
4306_4312del (p.Thr1436fs). All of these mutations were not
present in at least 140 control chromosomes, and the missense
mutations lead to the change of a well conserved amino acid.
This suggests that these mutations are pathogenic. Four novel
mutations target the eighth cytoplasmatic loop (c.3364delT)
or  NBF2  (c.3717T>G,  c.3871G>A,  and  c.4306_4312del).
Both domains are known hot spots for ABCC6 mutations.
Three other new mutations (c.2477T>C, c.3207C>A, and c.
2891G>C) are located in between NBF1 and NBF2. The c.
2477T>C mutation occurs just after NBF1 in an area targeted
by  three  previously  described  mutations  (c.2420G>A,  c.
2428G>A, and c.2458G>C). The c.3207C>A and c.2891G>C
mutations  target  less  frequently  mutated  domains  of  the
ABCC6  protein.  The  last  novel  mutation,  c.1685T>C,  is
uniquely located at the fifth extracellular loop before NBF1.
In our entire data set, at least one ABCC6 mutation was
identified in 127 (77%) of 166 probands in which there were
clinical suspicions of PXE. If we exclude the 20 patients
whose clinical diagnoses were questionable, we find at least
one mutation in 87% of probands. We found 40 different
mutations of which c.3421C>T (p.Arg1141X), c.3775delT,
Figure 3. Clinical optical features of pseudoxanthoma elasticum.
141514The retina of the right eye of case 5 shows peau d'orange
(diffuse,  mottled  hyperpigmentation)  and  angioid  streaks,  as
indicated by arrows. The angioid streaks resemble retinal blood
vessels and radiate from the optic disc to the periphery of the retina.
These two signs are the most frequent ophthalmologic features of
pseudoxanthoma elasticum.
and  a  deletion  of  exons  23-29  were  most  frequent.  The
p.Arg1141X mutation was found in 33% of alleles with a
mutation, and the latter two mutations were found in 14% and
13% of the alleles, respectively.
We did not find any mutation in 19 of the 146 (13%)
probands with a clinical diagnosis of PXE. In 51 of 146 (35%)
probands,  we  only  found  one  mutation.  As  inheritance  is
autosomal recessive, it is to be expected that these probands
have two mutations. Taken together, our missing rate per
allele is 35%, which suggests that a considerable part of the
mutations in our data set could not be identified.
Four studies in which the patients had clinically definite
PXE diagnoses reported missing rates of 3% [7] or 17.1%
[27] after sequencing and 12.3% [20], 14% [28], or 34%
[21]  after  denaturing  high-performance  liquid
chromatography (dHPLC). It is largely unclear why mutation
detection rates are different in several studies. What are the
possible explanations?
Geographic differences in patient populations: Most of
the patients in the above mentioned studies were from Italy
[27], Germany [20], France [28], and the United States [7,
21]. Most of our patients were from the Netherlands. Mutation
frequencies  differ  in  different  populations  [12].  It  is
conceivable  that  a  relatively  frequent  mutation  in  certain
populations  can  be  missed  by  the  techniques  used.
Heterozygous deletions of (or part of) the gene and mutations
in the promoter region and in introns can easily be missed.
Thirteen French PXE patients with at least one unidentified
mutation (18 unidentified alleles) after dHPLC were studied
with  a  quantitative  multiplex  PCR  of  short  fluorescent
fragments  (QMPSF)  [28].  Five  (novel)  deletions  were
detected. This reduced the total missing rate from 14% to 10%
of 130 alleles. Deletions can also be detected with multiplex
ligation-dependent  probe  amplification  (MLPA),  but  both
QMPSF and MLPA are not yet routinely used.
Sequencing: Sequencing the gene will yield additional
missense mutations, which are missed by dHPLC. This could
at least partly explain the high detection rate of Miksch et al.
[7].
Differences in patient selection: We did not have detailed
clinical information of all patients and, as a result, there were
some patients without a definite diagnosis of PXE. Some
patients could have a PXE-like phenotype as can be seen in
beta-thalassemia,  sickle  cell  anemia,  and  peri-umbilical
perforating PXE [1].
Digenic inheritance: Another, less likely, possibility is
digenic inheritance in the patients without two mutations. The
combination  of  one  ABCC6  mutation  with  a  mutation  in
another gene could lead to PXE. This could be different for
different populations.
Including  the  mutations  presented  here,  at  least  188
different ABCC6 mutations have been published to date in the
international  literature  (Appendix  1).  In  the  European
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121populations,  the  p.Arg1141X  mutation  is  by  far  the  most
prevalent (about 28% of alleles) while in the United States
population, the exon 23–29 deletion occurs most frequently
(also about 28% of alleles) [25,29]. The mutation distribution
in ABCC6 (Figure 1) shows three mutation hot spot domains:
the first and second NBF as well as the eighth cytoplasmatic
loop. Indeed, the latter is truly a hot spot for mutations since
the  frequent  mutations,  p.Arg1141X  and  the  exon  23–29
deletion, target this area. It has been suggested that the eighth
cytoplasmatic  loop  may  be  involved  in  ABCC6  substrate
recognition [12]. In our data set, mutations in these three
domains were found in 71% of the alleles with mutations.
Screening  of  the  involved  exons  16–18,  24,  and  27–30
together with the detection of the exon 23–29 deletion would
detect 95% of all of our mutations.
In all of our patients who had novel mutations, a diagnosis
of PXE could be made clinically (Table 1). The group was too
small to establish genotype-phenotype correlations. In the
data  set,  we  observed  considerable  intra-and  interfamilial
variations in phenotype, and we could not extract a genotype-
phenotype relationship either. Previous reports on potential
genotype-phenotype  correlations  revealed  variable  results.
Diagnosis at a significantly younger age and a higher number
of affected organs were found in the case of mutations that
lead to an absence of (functional) MRP6 [30]. It was suggested
that nonsense mutations were more frequently associated with
generalized involvement [27]. However, even in an extended
patient series, no clear genotype-phenotype correlation could
be found to date [7,19,21,25,27]. Besides, there is marked
variable expression within family members with the same
genotype [19,27,31].
In summary, we provide further evidence that ABCC6 is
the most important, and probably the only, causative gene
implicated in PXE. We added eight new mutations to the
ABCC6 mutation spectrum and supported the notion that most
mutations are present in the cytoplasmatic domains at the
carboxy terminal end of the protein, especially in the three
putative important functional domains of ABCC6 (NBF1,
NBF2, and the eighth cytoplasmatic loop).
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123Appendix  1.  All  ABCC6  mutations  which  are  implicated  in
pseudoxanthoma elasticum
To access the data, click or select the words “Appendix
1”. This will initiate the download of a compressed (zip)
archive  that  contains  the  file.  This  file  should  be
uncompressed with an appropriate program (the particular
program will depend on your operating system). We found
mutations  in  203  alleles.  The  fourth  column  shows  the
frequency of the different mutations among the alleles. Novel
mutations are bold and underlined.
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